Incidence and prevalence of multiple endocrine neoplasia 2B in Denmark: a nationwide study L39-L42 Dear Editor, Multiple endocrine neoplasia 2B (MEN2B) is an autosomal dominant inherited cancer syndrome associating medullary thyroid carcinoma (MTC), pheochromocytoma (PHEO), ganglioneuromatosis of the aerodigestive tract and facial, ophthalmologic and skeletal abnormalities. MEN2B is caused by the M918T and A883F mutation of the REarranged during Transfection (RET) proto-oncogene in approximately 95% and <5% of cases, respectively. Only very few other mutations have been reported to cause MEN2B. In approximately 75% of MEN2B patients, mutations occur as de novo (Wells et al. 2015) .
The epidemiology of MEN2B is poorly defined. A nationwide study from Northern Ireland reported of three MEN2B patients and 1,824,000 inhabitants alive at April 21, 2012, yielding a point prevalence of 1.65 per million (Znaczko et al. 2014) . However, it is unclear if this is representative of larger populations. A German study reported an MEN2B incidence (M918T carriers only) of 1.4 per million live births per year from 1991 to 2000 and estimated that at least half of all German RET carriers were captured (Machens et al. 2013) . Meanwhile, the incidence of MEN2B and M918T carriers in a complete population is undisclosed. We conducted a nationwide study of the incidence and prevalence of MEN2B in Denmark from 1941 to 2014.
This retrospective cohort study included 12 unique MEN2B patients identified through the following sources:
1. A nationwide RET cohort containing all patients (n = 1583) RET tested in Denmark from 1994 to 2014 (Mathiesen et al. 2017b The DATHYRCA database has prospectively registered all patients with thyroid carcinomas in Denmark since January 1996 (Londero et al. 2014 A total of 211 citations were found. Removal of seven duplicates and two triplets yielded 200 unique citations, of which 61 had Danish affiliations. Full-text was retrieved for all citations. Among the 61 citations nine reported of Danish MEN2B patients. The reference list of each citation was scrutinized to uncover patients published more than once. If needed an author of the concerned publication was contacted for clarification. Five of the nine citations mentioned a patient reported elsewhere. Two of the remaining four citations reported of patients already identified through the Danish RET cohort. The final two citations described a total of five patients (Rasmusson 1980 , Emmertsen 1984 . The author of each citation was contacted and four of the five MEN2B patients were identified. 6. A four-generation pedigree was created for all 10 MEN2B index patients using the Civil Registration System (www.cpr.dk) and the Danish National Archives (www.sa.dk/en/). Two additional MEN2B patients were ascertained.
Data were collected from medical records and when insufficient supplemented by previous publications of the patients.
Point prevalence was calculated as the number MEN2B patients alive at January 1 divided by the number of inhabitants alive at the same date. Incidence was calculated as the number of MEN2B patients born in each decade divided by the number of live births in Denmark for the respective decade. Patients born between 1941 and 1970 all died before RET testing was available and were solely diagnosed by the MEN2B phenotype. Patients born between 1971 and 2014 were diagnosed both by phenotype and by a verified RET germline mutation (M918T or A883F). Thus, to estimate the incidence of MEN2B in regards to mutation carriers the period of 1971-2000 was chosen, taking the precaution that some MEN2B born from 2001 to 2014 might still be unrecognized (mean age at diagnosis; 13 years (Brauckhoff et al. 2014) ). Danish population data were retrieved from Statistics Denmark (www.statbank.dk). All analyses were done using Stata 14.1 (StataCorp, USA). The investigation was approved by the Danish Health Authority (3-3013-395/2) and the Danish Data Protection Agency (13/19275). A total of 12 MEN2B patients from 10 unrelated families were included. Demographic, clinical and follow-up data are shown in Table 1 . All but patient 2 and 3 were classified as having a de novo mutation. The remaining 10 patients were recorded as index patients.
The point prevalence at January 1, 2015, was 1.06 per million (95% CI: 0.39-2.30) (six MEN2B patients and 5,659,715 inhabitants alive). If only including index patients in analysis, the point prevalence at January 1, 2012 and 2015, were 0.90 (95% CI: 0.29-2.10) and 0.88 (95% CI: 0.28-2.06) per million, respectively. Table 2 depicts the incidence of MEN2B by decade and mutation. The incidence from 1971 to 2000 was 2.6 (95% CI: 0.85-6.13) per million live births per year. If subdivided by mutation, the incidences of M918T and A883F carriers were 2.1 (95% CI: 0.57-5.38) and 0.5 (95% CI: 0.01-2.93) per million live births per year, respectively. In a German study, the incidence of M918T carriers from 1971 to 2000 was 1.0 per million live births per year (Machens et al. 2013 ). The differences in incidence probably reflect more or less complete ascertainment rather than a genuine difference.
This study shares limitations inherent with retrospective studies of rare diseases. Small sample sizes limiting generalization are often seen when studying rare diseases, as in this study. To increase sample size, we depleted virtually all possibilities to identify MEN2B patients in Denmark.
Also, the MEN2B diagnosis was not verified by RET mutations in four (no. 9-12) of the 12 included patients.
However, three (no. 9-11) demonstrated endocrine (MTC), musculoskeletal (marfanoid habitus, femoral epiphysiolysis, pes cavus, scoliosis), intestinal (constipation) and oral (mucosal neuromas) manifestations consistent with MEN2B. Pertinent data for the remaining patient (no. 12) revealed MTC, bilateral PHEO, constipation and neuromas of the tongue, also consistent with MEN2B.
The A883F carrier introduces heterogeneity into the study. However, inclusion of this carrier seems appropriate when calculating the overall MEN2B prevalence and incidence as such carriers have been identified in at least five other countries (Mathiesen et al. 2017a) .
The point prevalence of MEN2B index patients in Denmark was 0.90 per million at January 1, 2012. In a nationwide study consisting solely of MEN2B index patients from Northern Ireland, the point prevalence was 1.65 per million at April 21, 2012 (Znaczko et al. 2014) . This is considerably higher than seen in Denmark. However, no statistical significant difference can be proven. This might be due the small sample sizes.
In conclusion, the incidence and prevalence of MEN2B in this nationwide study does not differ significantly from that reported in Germany and Northern Ireland, respectively. 
